



# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE -United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/634,827	08/06/2003	Manfred Schudok	2481.1762-01	6761
5487	7590 03/29/2006		EXAMINER	
ROSS J. OEHLER			BALASUBRAMANIAN, VENKATARAMAN	
AVENTIS PHARMACEUTICALS INC. 1041 ROUTE 202-206			ART UNIT	PAPER NUMBER
MAIL CODE: D303A			1624	
BRIDGEWATER, NJ 08807			DATE MAILED: 03/29/2006	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
	10/634,827	SCHUDOK ET AL.				
Office Action Summary	Examiner	Art Unit				
	Venkataraman Balasubramanian	1624				
- The MAILING DATE of this communication appears on the cover sheet with the correspondence address - Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPL' WHICHEVER IS LONGER, FROM THE MAILING D. Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period of Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim will apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE	I.  lely filed  the mailing date of this communication.  D (35 U.S.C. § 133).				
Status						
Responsive to communication(s) filed on <u>06 Ja</u> This action is <b>FINAL</b> . 2b) ☐ This     Since this application is in condition for allowed closed in accordance with the practice under E	action is non-final. nce except for formal matters, pro					
Disposition of Claims						
<ul> <li>4)  Claim(s) 1-6,9 and 10 is/are pending in the appearance of the above claim(s) is/are withdraw 5)  Claim(s) 1-4,6 and 9 is/are allowed.</li> <li>6)  Claim(s) 5 and 10 is/are rejected.</li> <li>7)  Claim(s) is/are objected to.</li> <li>8)  Claim(s) are subject to restriction and/or</li> </ul>	wn from consideration.					
Application Papers						
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) acc Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct	epted or b) objected to by the Idrawing(s) be held in abeyance. See	e 37 CFR 1.85(a).				
11) The oath or declaration is objected to by the Ex	caminer. Note the attached Office	Action or form PTO-152.				
Priority under 35 U.S.C. § 119						
<ul> <li>12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority document</li> <li>2. Certified copies of the priority document</li> <li>3. Copies of the certified copies of the priority application from the International Bureau</li> <li>* See the attached detailed Office action for a list</li> </ul>	s have been received. s have been received in Applicati rity documents have been receive u (PCT Rule 17.2(a)).	on No ed in this National Stage				
Attachment(s)						
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:					

### **DETAILED ACTION**

Applicants' response, which included cancellation of claim 8, addition of new claim 10 and amendment to claims 4-6 and 9, filed on 1/6/2003, is made of record. Claims 1-6, 9 and 10 are now pending.

In view of applicants' response, the 112 second paragraph rejections made in the previous office action have been obviated. However, the following 112 first paragraph rejection, made in the previous office action, remains.

## Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 4-9 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

1. Claims 4-9 recite "at least one compound of claim 1" which renders these claims indefinite as it implies besides compound of claim1 as active ingredient it could have any other active ingredient. Replacement of "at least one compound of claim 1 with "one or more compound of claim 1" is suggested."

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 5 and 10 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for inhibiting blood clotting and restenosis does not

Art Unit: 1624

reasonably provide inhibiting and thereby treating all or any diseases associated with factor VIIa a or VIIa/TF activity. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention commensurate in scope with the claim.

The instant claims are drawn to "method of inhibiting factor VIIa, or VIIa/TF activity" in patient.

The scope of the claim as recited includes all or any disorders, any or all inflammatory diseases/disorders and any or all thromboembolic diseases including those yet to be discovered as due to factor VIIa. Instant claims 5 and 10 are reach through claims. A reach through claim is drawn to mechanistic, receptor or enzymatic binding based on which treating any or all diseases/disorders is reached. Reach through claims are in general considered lacking descriptive and enabling support for any or all diseases or disorders. As recited claim language includes any or all inflammatory disorders and diseases, any thromboembolic diseases, for which there is no enabling support in the specification. The instant compounds are disclosed to have factor VIIa inhibitory activity or VIIa/TF activity which relates to inhibition of thrombin. Next, applicant's attention is drawn to the Revised Utility and Written Description Guidelines, at 66 FR 1094-1099, 2001, wherein it is emphasized that 'a claimed invention must have a specific and substantial utility'. The disclosure in the instant case is not sufficient to enable the instantly claimed 'treating cardiovascular disorders' solely based on the inhibitory activity disclosed for the compounds. The state of the art is indicative of the requirement for undue experimentation. See Rauch et al., (PubMed

Application/Control Number: 10/634,827

Art Unit: 1624

Abstract enclosed) wherein with regards to antithrombotic therapies, it is stated "Current antithrombotic therapies available as long-term treatment for patients with cardiovascular disease are often not effective enough to prevent acute thrombotic events and deterioration of atherosclerosis". Also, Van Aken et al., (PubMed Abstract enclosed) with regards to therapeutic approach of thromboembolic disorders, expresses that 'thrombin inhibitors have limitations because their pharmacokinetics and anticoagulant effects are unpredictable'. (Only a few of the claimed diseases are discussed here to make the point of an insufficient disclosure, it does not definitely mean that the other diseases meet the enablement requirements).

In evaluating the enablement question, several factors are to be considered. Note *In re Wands*, 8 USPQ2d 1400 and *Ex parte Forman*, 230 USPQ 546. The factors include: 1) The nature of the invention, 2) the state of the prior art, 3) the predictability or lack thereof in the art, 4) the amount of direction or guidance present, 5) the presence or absence of working examples, 6) the breadth of the claims, and 7) the quantity of experimentation needed.

- 1) The nature of the invention: Therapeutic use of the compounds in treating all or any cardiovascular disorders even those yet to be discovered as related to Factor VII a activity and even that does not require factor VIIa inhibitory activity.
- 2) The state of the prior art: A very recent publication expressed that the pharmacokinetics and anticoagulant effects of thrombin inhibitors are unpredictable.
- 3) The predictability or lack thereof in the art: Applicants have not provided any competent evidence or disclosed tests that are highly predictive for the pharmaceutical

Application/Control Number: 10/634,827

Art Unit: 1624

use for treating any or all cardiovascular disorders with the instant compounds. Pharmacological activity in general is a very unpredictable area. Note that in cases involving physiological activity such as the instant case, "the scope of enablement obviously varies inversely with the degree of unpredictability of the factors involved". See *In re Fisher*, 427 F.2d 833, 839, 166 USPQ 18, 24 (CCPA 1970).

- 4) The amount of direction or guidance present and 5) the presence or absence of working examples: Specification has no working examples to show preventive effect thrombotic condition and the state of the art is that the effects of thrombin inhibitors are unpredictable.
- 6) The breadth of the claims: The instant claims embrace not only treatment Factor VIIa activity related disorders and VIIa/TF activity related diseases or disorders but also those which are not related to the Factor VIIa inhibiting activity of instant compounds.
- 7) The quantity of experimentation needed would be an undue burden to one skilled in the pharmaceutical arts since there is inadequate guidance given to the skilled artisan, regarding the pharmaceutical use, for the reasons stated above.

Thus, factors such as "sufficient working examples", "the level of skill in the art" and "predictability", etc. have been demonstrated to be sufficiently lacking in the instant case for the instant method claims. In view of the breadth of the claims, the chemical nature of the invention, the unpredictability of enzyme-inhibitor interactions in general, and the lack of working examples regarding the activity of the claimed compounds towards 'treating' the variety of cardiovascular disorders of the instant claims, one having ordinary skill in the art would have to undergo an undue amount of

experimentation to use the instantly claimed invention commensurate in scope with the claims.

MPEP 2164.01(a) states, "A conclusion of lack of enablement means that, based on the evidence regarding each of the above factors, the specification, at the time the application was filed, would not have taught one skilled in the art how to make and/or use the full scope of the claimed invention without undue experimentation. In re Wright, 999 F.2d 1557,1562, 27 USPQ2d 1510, 1513 (Fed. Cir. 1993)." That conclusion is clearly justified here. Thus, undue experimentation will be required to make Applicants' invention.

This rejection is same as made in the previous office action but now applied to newly added claim 10 for reasons indicated above. Applicants' argument to overcome this rejection is not persuasive.

As noted above, the instant claims are reach through claims. Reach through claims, in general have a format drawn to mechanistic, receptor binding or enzymatic functionality and thereby reach through any or all diseases, disorders or conditions for which they lack written description and enabling disclosure in the specification.

In the instant case, it appears that, because the instant compounds inhibit VIIa or VIIa/TF activity which are said to be present in several tissues, it is recited that, based on the inhibition of VIIa or VIIa/TF activity, any or all diseases can be treated with the instant compounds for which there is no adequate written description and enabling disclosure.

Application/Control Number: 10/634,827

4004

Art Unit: 1624

Contrary to applicants' urging, one trained need to do extensive experimentation with the large genus of compounds and various diseases to identify those useful for treating. This is clearly an undue burden.

Hence, this rejection is proper and is maintained.

### Allowable Subject Matter

Claims 1-4, 6 and 9 are allowable, barring any prior art finding in a subsequent search. Said claims 1-4 and 9 would be allowed since compound, specific species and process of making, method of use embraced in these claims are not taught or suggested by the art of record or from a search in the relevant art area.

#### Conclusion

Any inquiry concerning this communication from the examiner should be addressed to Venkataraman Balasubramanian (Bala) whose telephone number is (571) 272-0662. The examiner can normally be reached on Monday through Thursday from 8.00 AM to 6.00 PM. The Supervisory Patent Examiner (SPE) of the art unit 1624 is James O. Wilson whose telephone number is (571) 272-0661.

The fax phone number for the organization where this application or proceeding is assigned (571) 273-8300. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (571) 272-1600.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAG. Status

Application/Control Number: 10/634,827 Page 8

Art Unit: 1624

information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-2 17-9197 (toll-free).

Venkulanawa Balasubramanan Venkataraman Balasubramanian

3/17/2006